Eli Lilly's Zepbound weight-loss drug cuts heart failure risks, study finds
An Eli Lilly & Co. Zepbound injection pen is prepared in the Brooklyn borough of New York, U.S., on Thursday,…
health care industry
Biogen (BIIB) Q2 2024 Results
Biogen The company on Thursday reported second-quarter earnings and revenue, which beat estimates and raised its full-year guidance as the…
Moderna (MRNA) earnings in the second quarter of 2024
Modern On Thursday, it reported second-quarter revenue that beat expectations but cut its full-year sales outlook, citing lower expected sales…
23andMe CEO Anne Wojcicki presents a proposal to take the company private
A sign is posted in front of 23andMe headquarters in Sunnyvale, California, on February 1, 2024. Justin Sullivan | Getty…
GLP-1s are being tested for uses beyond weight loss and diabetes
Slimming syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Image…
GEHC gives reasons to look beyond China's temporary woes and stocks rise again
GE Healthcare reported a mixed second quarter on Wednesday morning, and shares initially dipped sharply. Shares then reversed higher as…
Eisai Biogen's Leqembi Alzheimer's drug shows benefits over three years
The newly FDA-approved Alzheimer's treatment, Leqembi, will be prepared at Abington Neurological Associates in Abington, Pennsylvania on Tuesday, November 7,…
A bullish bet on major banks is lost in the rotation of technology stocks
Each weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
Novo Nordisk's liraglutide GLP-1 may slow the progression of Alzheimer's
A box of the drug Victoza, manufactured by Novo Nordisk Pharmaceutical, sits on a pharmacy counter in Provo, Utah, January…
Neuralink rival Synchron offers thought control with Apple Vision Pro
Mark uses the Vision Pro with his BCI Courtesy of Synchron Neurotechnology startup Synchron announced Tuesday that it has connected…